Assessments of MammaPrint and EndoPredict tests withdrawn in Sweden

15

Sep 2021

On August 19, 2021, the Dental and Pharmaceutical Benefits Agency (TLV) has announced the withdrawal of two following assessments:

  • MammaPrint test, upon the decision of the Medical Technology Product Council (reason not disclosed);
  • EndoPredict test, as the manufacturer (Myriad Genetics) chose to refrain from participating in the health economic evaluation.

Earlier this year, the assessment was conducted for Oncotype and Prosigna tests as well. These assessments were accomplished, and the reports were released by TLV in July 2021.

The full details in Swedish can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

21

Sep 2021

In August 2021, the mini-HTA evaluation of the robot-assisted percutaneous coronary intervention was released. The method was described as safe and effective. After the introduction into the clinical practice, the method should be followed up for two years with a sufficient number of procedures to understand the real benefit. All procedures are to be registered in the Norwegian Registry for Invasive Cardiology.

Read more

17

Sep 2021

In mid-August 2021, the Finnish Coordinating Center for Health Technology Assessment announced the release of the four accomplished rapid hospital assessments (HTA) performed by the Helsinki University Hospital. The accomplished rapid HTAs concern the cardiovascular, peripheral vascular, and endoscopy technology groups.

Read more

16

Sep 2021

On August 17, 2021, the National Institute of Public Health released a rapid HTA report on the evaluation of PD-L1 assays in urothelial carcinoma commissioned by the Ordering Forum. This assessment does not provide any conclusions on the effectiveness of various treatment strategies in the treatment of urothelial carcinoma in adults.

Read more

09

Sep 2021

On August 23, 2021, the Institute for Quality and Efficiency in Health Care (IQWiG) has presented an updated draft version (6.1) of its general methods. The interested parties can submit written comments until the deadline of October 4, 2021.

Read more

08

Sep 2021

At the end of August 2021, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) has initiated a theme survey on digital image diagnostics to identify new and innovative technology that may become important in Swedish healthcare. This could lead to potential inclusion of the technology in the Orderly introduction of medical technologies framework. The suggestions could be submitted no later than September 24, 2021.

Read more